Oncotelic Therapeutics (OTCQB: OTLC) has launched an AI-powered GMP manufacturing services platform designed to address a critical bottleneck for emerging biotechnology companies. The platform integrates Oncotelic's proprietary PDAOAI architecture, digital batch records, and intelligent robotics developed in partnership with TechForce Robotics. It targets emerging biotechs, contract development and manufacturing organizations (CDMOs), cell and gene therapy developers, and radiopharmaceutical manufacturers that cannot justify building full GMP infrastructure in-house.
The announcement, made in June, marks a strategic move by Oncotelic to leverage its existing AI-GMP capabilities, which already operate inside its SAPU manufacturing base. By offering these services externally, the company positions the platform as both a pipeline accelerator and a potential new revenue line. For smaller companies, the road from discovery to clinical execution often breaks down at manufacturing, which requires good manufacturing practices, regulatory documentation, batch records, quality systems, process monitoring, and scalable production. Building or accessing that infrastructure is slow, expensive, and operationally overwhelming.
Oncotelic's platform aims to alleviate these challenges by providing a turnkey solution. The AI-driven system automates key aspects of manufacturing, including digital batch records that ensure compliance and traceability. Intelligent robotics further streamline production processes, reducing the risk of human error and increasing efficiency. The platform is built on Oncotelic's PDAOAI architecture, which uses artificial intelligence to optimize manufacturing workflows and quality control.
The launch comes at a time when the biopharmaceutical industry is increasingly turning to AI and automation to reduce costs and accelerate timelines. By offering GMP manufacturing as a service, Oncotelic provides a viable alternative for companies that lack the resources to build their own facilities. This could be particularly impactful for cell and gene therapy developers, who face unique manufacturing challenges due to the complexity of their products.
Investors can find the latest news and updates relating to OTLC in the company's newsroom at https://ibn.fm/OTLC. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology, immunotherapy, and high-unmet-need indications.
This development underscores the growing importance of AI in pharmaceutical manufacturing and the potential for innovative service models to democratize access to GMP capabilities. As more biotechs adopt these technologies, the industry may see faster progression of therapies from lab to clinic, ultimately benefiting patients.
For more information about Oncotelic and its AI-GMP platform, visit the company's website or follow updates through InvestorWire, a specialized communications platform that syndicates press releases for private and public companies. InvestorWire is part of the Dynamic Brand Portfolio @IBN, which provides access to a vast network of wire solutions, article syndication to 5,000+ outlets, and social media distribution.
